Isolation and characterization of erlotinib-resistant human non-small cell lung cancer A549 cells

被引：8

作者：

Ikeda, Ryuji ^{[2
]}

Vermeulen, Lee C. ^{[1
,3
]}

Lau, Elim ^{[4
]}

Jiang, Zhisheng ^{[4
]}

Kavanaugh, Shannon M. ^{[4
]}

Yamada, Katsushi ^{[2
]}

Kolesar, Jill M. ^{[1
,4
]}

机构：

[1] Univ Wisconsin, Sch Pharm, Div Pharma Practice, Madison, WI 53705 USA

[2] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Clin Pharm & Pharmacol, Kagoshima, Japan

[3] Univ Wisconsin, Hosp & Clin, Ctr Drug Policy, Madison, WI 53705 USA

[4] Univ Wisconsin, Paul P Carbone Comprehens Canc Ctr, Madison, WI 53705 USA

来源：

ONCOLOGY LETTERS | 2011年 / 2卷 / 01期

关键词：

erlotinib; epidermal growth factor receptor; fibroblast growth factor 2; p21; GROWTH-FACTOR-RECEPTOR; PHASE-III TRIAL; ACQUIRED-RESISTANCE; THERAPY; EGFR; CHEMOTHERAPY; ANTAGONISTS; INHIBITORS; MUTATIONS; GEFITINIB;

D O I：

10.3892/ol.2010.198

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Erlotinib, an epidermal growth factor receptor (EGER) tyrosine kinase inhibitor, is an effective therapy for non-small cell lung cancer (NSCLC). However, resistance to erlotinib reduces its efficacy. To investigate the basis of erlotinib resistance, we isolated erlotinib-resistant human NSCLC A549 cells, termed A549/ER cells. The A549/ER cells were found to be resistant to erlotinib, as well as paclitaxel and gemcitabine. We then performed a PCR array to investigate the resistance to erlotinib in A549/ER cells. EGFR expression in A549/ER cells was decreased compared to A549 cells. The expression of fibroblast growth factor 2 (FGF2) and p21 in A549/ER was increased when compared to A549 cells. Our results suggest that the down-regulation of EGFR and up-regulation of FGF2 is related to resistance to erlotinib in A549/ER cells.

引用

页码：91 / 94

页数：4

共 19 条

[1]

Abukhdeir Abde M., 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000744

[2] American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer [J].

Azzoli, Christopher G. ;

Baker, Sherman, Jr. ;

Temin, Sarah ;

Pao, William ;

Aliff, Timothy ;

Brahmer, Julie ;

Johnson, David H. ;

Laskin, Janessa L. ;

Masters, Gregory ;

Milton, Daniel ;

Nordquist, Luke ;

Pfister, David G. ;

Piantadosi, Steven ;

Schiller, Joan H. ;

Smith, Reily ;

Smith, Thomas J. ;

Strawn, John R. ;

Trent, David ;

Giaccone, Giuseppe .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (36) :6251-6266

[3] Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor - Mutant lung adenocarcinomas with acquired resistance to kinase inhibitors [J].

Balak, Marissa N. ;

Gong, Yixuan ;

Riely, Gregory J. ;

Somwar, Romel ;

Li, Allan R. ;

Zakowski, Maureen F. ;

Chiang, Anne ;

Yang, Guangli ;

Ouerfelli, Ouathek ;

Kris, Mark G. ;

Ladanyi, Marc ;

Miller, Vincent A. ;

Pao, William .

CLINICAL CANCER RESEARCH, 2006, 12 (21) :6494-6501

[4] Drug therapy: EGFR antagonists in cancer treatment [J].

Ciardiello, Fortunato ;

Tortora, Giampaolo .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (11) :1160-1174

[5] HCT116 cells deficient in p21Waf1 are hypersensitive to tyrosine kinase inhibitors and adriamycin through a mechanism unrelated to p21 and dependent on p53 [J].

Ferrandiz, Nuria ;

Martin-Perez, Jorge ;

Blanco, Rosa ;

Donertas, Derya ;

Weber, Axel ;

Eilers, Martin ;

Dotto, Paolo ;

Dolores Delgado, M. ;

Leon, Javier .

DNA REPAIR, 2009, 8 (03) :390-399

[6]

Gartel AL, 2002, MOL CANCER THER, V1, P639

[7] Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial [J].

Gatzemeier, Ulrich ;

Pluzanska, Anna ;

Szczesna, Aleksandra ;

Kaukel, Eckhard ;

Roubec, Jaromir ;

De Rosa, Flavio ;

Milanowski, Janusz ;

Karnicka-Mlodkowski, Hanna ;

Pesek, Milos ;

Serwatowski, Piotr ;

Ramlau, Rodryg ;

Janaskova, Terezie ;

Vansteenkiste, Johan ;

Strausz, Janos ;

Manikhas, Georgy Moiseevich ;

Von Pawel, Joachim .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (12) :1545-1552

[8] Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy [J].

Gazdar, Adi F. .

CANCER AND METASTASIS REVIEWS, 2010, 29 (01) :37-48

[9] Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer [J].

Hirsch, F. R. ;

Varella-Garcia, M. ;

Cappuzzo, F. .

ONCOGENE, 2009, 28 :S32-S37

[10] ERBB receptors and cancer: The complexity of targeted inhibitors [J].

Hynes, NE ;

Lane, HA .

NATURE REVIEWS CANCER, 2005, 5 (05) :341-354

← 1 2 →